The last decade has ushered in an exciting new era in the pathophysiology and treatment of atopic dermatitis (AD). In this book, we shed light on the latest breakthroughs in systemic treatments for moderate-to-severe AD. In particular, we focus on the role and indication of JAK inhibitors, the role of natural killer cells in opening doors to new therapies, newly validated treatments, disease-based community data of current treatments, and the most recent clinical efficacy data of novel agents that have revolutionized the management of moderate-to-severe AD.
